Retatrutide Shows 28% Weight Loss in Phase 3 Trial - Summary - MDSpire

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

  • By

  • Kathryn Wighton

  • May 21, 2026

Share

Objective:

To evaluate the efficacy and safety of retatrutide, a triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity.

Key Findings:
  • Participants on retatrutide 12 mg experienced a mean body weight reduction of 28.3% (70.3 pounds).
  • 45.3% of participants on 12 mg achieved at least 30% body weight reduction.
  • 65.3% of participants on 12 mg achieved a BMI below 30 by week 80.
  • At 104 weeks, participants on 12 mg had a mean weight reduction of 30.3% (85.0 pounds).
  • Retatrutide treatment led to reductions in waist circumference, triglycerides, systolic blood pressure, and other health markers.
Interpretation:

Retatrutide demonstrates significant weight loss and health improvements in adults with obesity, with a favorable efficacy profile compared to placebo.

Limitations:
  • Adverse events were primarily gastrointestinal, with discontinuation rates higher in retatrutide groups compared to placebo.
  • Long-term safety and efficacy data beyond 104 weeks are still pending.
Conclusion:

Retatrutide shows promising results for weight management in obese adults, with ongoing studies expected to provide further insights.

Original Source(s)

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

  • by Kathryn Wighton

  • May 21, 2026

Related Content

High-Resolution Spectroscopy on a Silicon Chip

A photonic–computational spectrometer smaller than 0.002 mm² delivers picometer-scale spectral resolution 

  • May 21, 2026

  • 2 min
Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.

Retirement Match Could Reach $600,000

Financial model suggests that early retirement contributions during residency may compound substantially by retirement age under long-term market assumptions.